Preclinical data have suggested that the combinatorial targeting of EGFR and KRAS G12C leverages a dual-pathway blockade to inhibit tumor growth more effectively and may overcome the adaptive resistance to KRAS G12C inhibition [70]. Here, KRAS is linked to neoplasm.